
Pediatric Patients: Dolutegravir tablets may be taken with or without food.
Treatment-Naïve or Treatment-Experienced INSTI-Naïve: The recommended dose of dolutegravir tablets in pediatric patients weighing at least 30 kg is provided in Table 11. (See Table 11.)

Safety and efficacy of dolutegravir tablets have not been established in pediatric patients who are INSTI-experienced with documented or clinically suspected resistance to other INSTIs (raltegravir, elvitegravir).